Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis

Diabetes Care

Volumn 28, Issue 2, 2005, Pages 454-460

  Cruciani, Mario ^a   Lipsky, Benjamin A ^b,c,f   Mengoli, Carlo ^d   De Lalla, Fausto ^e  

^a Center of Preventive Medicine   (Italy)

^b General Internal Medicine Clinic   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

^e SAN BORTOLO HOSPITAL   (Italy)

^f VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETIC FOOT; DRUG EFFICACY; FOOT SURGERY; HUMAN; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; META ANALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME; WOUND HEALING;

AMPUTATION; BACTERIAL INFECTIONS; DIABETIC FOOT; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LIMB SALVAGE; RANDOMIZED CONTROLLED TRIALS;

EID: 12844274898     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.2.454     Document Type: Article

References (54)

1. Moulik PK, Mtonga R, Gill GV: Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care 26:491-494, 2003
2. Reiber GE, Lipsky BA, Gibbons GW: The burden of diabetic foot ulcers. Am J Surg 176 (Suppl. 2A):5S-10S, 1998
3. International Working Group on the Diabetic Foot: International Consensus on the Diabetic Foot. Brussels, International Diabetes Federation, CD-ROM, 2003
4. Lipsky BA, Berendt AR: Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev 16 (Suppl. 1):S42-S46, 2000
5. Sato N, Shimizu H: Granulocyte-colony stimulating factor improves an impaired bactericidal function in neutrophils from STZ-induced diabetic rats. Diabetes 42:470-473, 1993
6. Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B: Impaired leucocyte functions in diabetic patients. Diabet Med 14:29-34, 1997
7. Geerlings SE, Hoepelman AI: Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26:259-265, 1999
8. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME: Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 350:855-859, 1997
9. Nelson S, Heyder AM, Stone J, Bergeron MG, Daugherty S, Peterson G, Fotheringham N, Welch W, Milwee S, Root R: A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 182:970-973, 2000
10. Sato N, Kashima K, Tanaka Y, Shimizu H, Mori M: Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes 46:133-137, 1997
11. Dale DC, Liles WC, Summer WR, Nelson S: Review: granulocyte colony-stimulating factor: role and relationships in infectious diseases. J Infect Dis 172: 1061-1075, 1995
12. Hartung T: Granulocyte colony-stimulating factor: its potential role in infectious disease. Aids 13 (Suppl. 2):S3-S9, 1999
13. Root RK, Dale DC: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 179 (Suppl. 2):S342-S352, 1999
14. Hubel K, Engert A: Granulocyte transfusion therapy for treatment of infections after cytotoxic chemotherapy. Onkologie 26:73-79, 2003
15. Murata A: Granulocyte colony-stimulating factor as the expecting sword for the treatment of severe sepsis. Curr Pharm Des 9:1115-1120, 2003
16. Nelson S: Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview. Clin Infect Dis 18 (Suppl. 2):S197-S204, 1994
17. de Lalla F, Nicolin R, Lazzarini L: Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for Streptococcus pneumoniae meningitis in non-neutropenic adult patients: a pilot study. J Antimicrob Chemother 46:843-846, 2000
18. Peck KR, Son DW, Song JH, Kim S, Oh MD, Choe KW: Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro. J Korean Med Sci 16:39-44, 2001
19. L'Abbe K, Detsky A, O'Rourke K: Meta-analysis in clinical research. Ann Intern Med 107:224-233, 1987
20. Oakes M: The logic and role of meta-analysis in clinical research. Stat Methods Med Res 2:147-160, 1993
21. Naylor CD: Meta-analysis and the meta-epidemiology of clinical research. BMJ 315:617-619, 1997
22. Pagliaro L: Preparing and interpreting meta-analysis in clinical research. Arch Ital Urol Androl 69:217-225, 1997
23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12, 1996
24. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959
25. DerSimonian R: Meta-analysis in the design and monitoring of clinical trials. Stat Med 15:1237-1248, 1996; discussion 15: 1249-1252, 1996
26. DerSimonian R: Meta-analysis in the design and monitoring of clinical trials. Stat Med 15:1237-1248, 1996; discussion 15: 1249-1252, 1996
27. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
28. Woolf B: On estimating the relation between blood group and disease. Ann Intern Med 19:251-253, 1955
29. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318:1728-1733, 1988
30. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997
31. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
32. Cochran WG: The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 24:295-313, 1968
33. Wermuth N, Cochran WG: Detecting systematic errors in multi-clinic observational data. Biometrics 35:683-686, 1979
34. Higgins J, Thompson S, Deeks J, Altman D: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003
35. Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A: A systematic review of foot ulcer in patients with type 2 diabetes mellitus. II: treatment. Diabet Med 16:889-909, 1999
36. de Lalla F, Pellizzer G, Strazzabosco M, Martini Z, Du Jardin G, Lora L, Fabris P, Benedetti P, Erle G: Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 45:1094-1098, 2001
37. Yonem A, Cakir B, Guler S, Azal OO, Corakci A: Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 3:332-337, 2001
38. Kastenbauer T, Hornlein B, Sokol G, Irsigler K: Evaluation of granulocyte-colony stimulating factor (filgrastim) in infected diabetic foot ulcers. Diabetologia 46:27-30, 2003
39. Viswanathan V, Mahesh U, Jayaraman M, Shina K, Ramachandram A: Beneficial role of granulocyte colony stimulating factor in foot infection in diabetic patients. J Assoc Physicians India 51:90-91, 2003
40. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL: Growth factors in the treatment of diabetic foot ulcers. Br J Surg 90: 133-146, 2003
41. Lazareth I: X. Local care and medical treatment of ischemic trophic disorders in the diabetic patients. J Mal Vasc 27:287-288, 2002; discussion 27: 301-283, 2002
42. Lazareth I: X. Local care and medical treatment of ischemic trophic disorders in the diabetic patients. J Mal Vasc 27:287-288, 2002; discussion 27: 301-283, 2002
43. Dale DC: Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 62 (Suppl. 1):1-15, 2002
44. Kreyden OP, Hafner J, Burg G, Nestle FO: Case report on therapy with granulocyte stimulating factor in diabetic foot. Hautarzt 52:327-330, 2001
45. Edmonds M, Bates M, Doxford M, Gough A, Foster A: New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev 16 (Suppl. 1):S51-S54, 2000
46. Bakker K, Schaper NC: New developments in the treatment of diabetic foot ulcers. Ned Tijdschr Geneeskd 144:409-412, 2000
47. Hafner J, Burg G:Dermatological aspects in prevention and treatment of the diabetic foot syndrome. Schweiz Rundsch Med Prax 88:1170-1177, 1999
48. Chantelau E, Kimmerle R: Granulocyte-colony-stimulating factor in diabetic foot infection (Letter). Lancet 351:370, 1998
49. Baddour LM: Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Curr Infect Dis Rep 4:413-414, 2002
50. Agrawal R, Agrawal S, Beniwal S, Joshi C, Kochar D: Granulocyte- macrophage colony-stimulating factor in foot ulcers. The Diabetic Foot Summer:1-8, 2003
51. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ: A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care 24:84-88, 2001
52. Lipsky BA: A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20 (Suppl. 1):S68-S77, 2004
53. Ashry HR, Lavery LA, Armstrong DG, Lavery DC, van Houtum WH: Cost of diabetes-related amputations in minorities. J Foot Ankle Surg 37:186-190, 1998
54. Tennvall GR, Apelqvist J, Eneroth M: Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics 18:225-238, 2000